<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Medicine/Surgery/Urology.xml">
<title>Urology RSS : Gourt</title>
<link>http://www.gourt.com/Health/Medicine/Surgery/Urology.xml</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2009-07-03T21:41+55:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Urology RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_florida/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_california/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_texas/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_texas/page_7.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_nevada/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_south_carolina/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_oregon/page_4.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_pennsylvania/page_5.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_california/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_9.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_10.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_illinois/page_8.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_10.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_georgia/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_3.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_4.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_5.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_6.html" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156242.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156246.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156109.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156080.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/156029.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155919.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155926.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155771.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155731.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155739.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155742.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155659.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155599.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155582.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155446.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155406.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155420.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155348.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155240.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155251.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/155008.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/154875.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/154824.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/154747.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/154748.php" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/9/6" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/9/5" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/9/4" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/9/3" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/9/2" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/9/1" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/8/21" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/8/20" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/8/19" />
  <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2490/8/18" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_florida/page_1.html">
<title>Permanent Urology Job in Bradenton Florida with Universal Health Services, Inc.</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_florida/page_1.html</link>
<description><![CDATA[Urology Opening - da Vinci Robot- Coastal FL  Manatee Memorial hospital in beautiful Bradenton, FL is assisting a busy well established Urology practice recruit a new Urologist to join their group. This ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_california/page_1.html">
<title>Permanent Urology Job in Lancaster California with Universal Health Services, Inc.</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_california/page_1.html</link>
<description><![CDATA[Great Urology Opening near S. California  Lancaster Community Hospital, in Lancaster, CA is assisting in the recruitment of a new Urologist to the community of Lancaster, CA. The practice is a well established, ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_texas/page_2.html">
<title>Permanent Urology Job in Laredo Texas with Universal Health Services, Inc.</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_texas/page_2.html</link>
<description><![CDATA[Urology - Private Practice - Ownership buy in to Surgery Center and Hospital!  Doctors Hospital of Laredo is recruiting a new Urologist. Due to rapid growth in the community there is great need for additional ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_texas/page_7.html">
<title>Permanent Urology Job in McAllen/Edinburg Texas with Universal Health Services, Inc.</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_texas/page_7.html</link>
<description><![CDATA[New Urology Practice Opportunity - Texas  South Texas Health System is recruiting a new Urologist to the communities of McAllen and Edinburg.       The Urologist will have the option of starting up a ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_nevada/page_1.html">
<title>Permanent Urology Job in Sparks Nevada with Universal Health Services, Inc.</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_nevada/page_1.html</link>
<description><![CDATA[Urology - Private Practice  Discover Sparks, Nevada - you'll be pleasantly surprised!  Northern Nevada Medical Center, in Sparks, Nevada is assisting in the recruitment of a new Urologist to the community ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_south_carolina/page_1.html">
<title>Permanent Urology Job in Aiken South Carolina with Universal Health Services, Inc.</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_south_carolina/page_1.html</link>
<description><![CDATA[Urology Private Practice - near Augusta GA - Associate to Partner offered!     Established private practice in Aiken SC is seeking a new Urologist due to the growth in the referrals and caseload demand ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_oregon/page_4.html">
<title>Permanent Urology Job in Northwest Oregon with Providence Health &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_oregon/page_4.html</link>
<description><![CDATA[ NW Oregon  Providence Health & Services is seeking a BE/BC Urologist to join us in a small scenic community near Portland. Excellent compensation and light call (shared with established Urology practice ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_pennsylvania/page_5.html">
<title>Permanent Urology Job in Erie Pennsylvania with Saint Vincent Health Center</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_pennsylvania/page_5.html</link>
<description><![CDATA[ PRIVATE PRACTICE  Saint Vincent Health System   A brief summary of the features of this position, the hospital and the community follows: This 4-person group  is based mainly at Saint Vincent Health ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_california/page_2.html">
<title>Permanent Urology Job in Tarzana California with Providence Health &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_california/page_2.html</link>
<description><![CDATA[ San Fernando Valley of Los Angeles - Providence Tarzana Medical Center is partnering with an excellent private practice in search of a quality Urologist to serve the community. Excellent compensation ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_2.html">
<title>Permanent Urology Job in Spokane Washington with Providence Health &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_2.html</link>
<description><![CDATA[ Spokane, Washington  Providence Health & Services and an established single-specialty private practice are partnering to bring a new BE/BC Urologist to serve this sunny eastern Washington community. ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_9.html">
<title>Permanent Urology Job in Olympia Washington with Providence Health</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_9.html</link>
<description><![CDATA[Providence Health & Services is partnering with a private general urology practice to bring another urologist to serve this beautiful Pacific Northwest city. Good benefits with early partnership track. ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_10.html">
<title>Permanent Urology Job in Centralia Washington with Providence Health</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_washington/page_10.html</link>
<description><![CDATA[ Centralia, Washington -- Providence Centralia Hospital is seeking an excellent BE/BC Urologist to join us in beautiful southwest Washington state. Full time, with excellent salary plus production bonus ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_illinois/page_8.html">
<title>Permanent Urology Job in Mattoon Illinois with Sarah Bush Lincoln Health Center</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_illinois/page_8.html</link>
<description><![CDATA[ Roger Rives, M.D. and David DiDomenico, M.D., D.O. have a busy and steadily growing general Urology practice and are seeking a third person to join their group. Their office is located in the Medical ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_10.html">
<title>Permanent Urology Job in South Central, KS Kansas with Rural Health Education &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_10.html</link>
<description><![CDATA[ Urologist  Option to be hospital employed or in a solo practice.  There are currently no other urologists on staff.  The hospital is a 69-bed acute care facility with a 51-bed short-term and long-term ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_2.html">
<title>Permanent Urology Job in North Central Kansas with Rural Health Education &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_2.html</link>
<description><![CDATA[ KRC.0708.0701.13   Urologist  New position for a two-campus, 99 bed, regional acute care hospital.  The modern facility offers full laparoscopic system, family birthing rooms, a well-equipped intensive ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_georgia/page_2.html">
<title>Permanent Urology Job in Columbus Georgia with St. Francis Hospital</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_georgia/page_2.html</link>
<description><![CDATA[ St. Francis Hospital is assisting a local practice in recruitment of a partner to meet the community need for Urology in Columbus.    This practice seeks BC/BE Urologist with interest in  laparoscopic ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_3.html">
<title>Permanent Urology Job in Southwest Kansas with Rural Health Education &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_3.html</link>
<description><![CDATA[ KRC.0908.2302.03C  Urologist position available at a 99-bed acute care facility accredited by the Joint Commission on Accreditation of Healthcare Organizations, which offers traditional comprehensive ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_4.html">
<title>Permanent Urology Job in Northwest Kansas with Rural Health Education &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_4.html</link>
<description><![CDATA[ KRC.0508.0801.31  Urologist position available to join 3 physician urology group for a 190+ bed, state of the art medical center and wellness facility. There are currently 90 physicians on their active ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_5.html">
<title>Permanent Urology Job in Southeast Kansas with Rural Health Education &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_5.html</link>
<description><![CDATA[ Urologist position available for solo practice. The 190-bed admitting hospital provides full service general acute care including CT, ER, home health, hospice, ICU, MRI, nuclear medicine, ultrasound, ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_6.html">
<title>Permanent Urology Job in South Central Kansas with Rural Health Education &#x26; Services</title>
<link>http://www.physemp.com/physician_jobs/all_urology_jobs_in_kansas/page_6.html</link>
<description><![CDATA[ KRC.0507.1309.05C  Urologist for progressive multi-specialty group practice. There are currently 11 specialties and 23 physicians and 5 mid-levels on staff.  Salary for this position is $350,000 (guarantee ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156242.php">
<title>New Discovery To Aid In Diagnosis And Treatment Of Kidney Disease</title>
<link>http://www.medicalnewstoday.com/articles/156242.php</link>
<description><![CDATA[Researchers from Boston University School of Medicine (BUSM) in collaboration with scientists at the University of Louisville and the University of Nice Sophia Antipolis in France, have identified the target antigen PLA2R in patients with idiopathic membranous nephropathy (kidney disease), which has implications for the diagnosis and treatment of this disease. These findings appear in the July 2 issue of the New England Journal of Medicine.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156246.php">
<title>News From The Journal Of Clinical Investigation, July 1, 2009</title>
<link>http://www.medicalnewstoday.com/articles/156246.php</link>
<description><![CDATA[GENE THERAPY: Defining immune pathways limiting gene therapy    In gene therapy, recombinant adeno-associated viruses (AAVs) are commonly used vehicles for delivering the therapeutic gene into target cells. One factor limiting the clinical application of such vehicles is that the immune system often mounts a response against the AAV vehicle.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156109.php">
<title>Prostate-Specific Antigen: To Test Or Not To Test, From Harvard Men&#x27;s Health Watch</title>
<link>http://www.medicalnewstoday.com/articles/156109.php</link>
<description><![CDATA[One of the most controversial issues in men's health is whether men should routinely have a blood test for prostate-specific antigen (PSA) to screen for prostate cancer. Some experts argue that PSA testing saves lives by helping detect this common form of cancer early. Others say it triggers unnecessary treatment that disrupts many more lives than it saves.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156080.php">
<title>FDA Approves Feraheme&#x2122; To Treat Iron Deficiency Anemia In Adult Chronic Kidney Disease Patients</title>
<link>http://www.medicalnewstoday.com/articles/156080.php</link>
<description><![CDATA[AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme™ (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. The recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg IV injection three to eight days later.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/156029.php">
<title>Nephrogenic Systemic Fibrosis And  Gadolinium-Based Contrast Agents</title>
<link>http://www.medicalnewstoday.com/articles/156029.php</link>
<description><![CDATA[Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the Mayo Clinic Florida, Jacksonville, FL. NSF is a rare and serious syndrome that leads to fibrosis of the skin, joints and even internal organs. Some research indicates NSF is caused by gadolinium-based contrast agents that are commonly used today during MR procedures.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155919.php">
<title>Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients With Complicated Urinary Tract Infections</title>
<link>http://www.medicalnewstoday.com/articles/155919.php</link>
<description><![CDATA[Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155926.php">
<title>Even At High Doses, Gadolinium-Based Contrast Agents Cannot By Themselves Cause Patients To Develop Nephrogenic Systemic Fibrosis</title>
<link>http://www.medicalnewstoday.com/articles/155926.php</link>
<description><![CDATA[Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the Mayo Clinic Florida, Jacksonville, FL. NSF is a rare and serious syndrome that leads to fibrosis of the skin, joints and even internal organs. Some research indicates NSF is caused by gadolinium-based contrast agents that are commonly used today during MR procedures.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155771.php">
<title>DuoCort: New Chronotherapy For Adrenal Insufficiency</title>
<link>http://www.medicalnewstoday.com/articles/155771.php</link>
<description><![CDATA[DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency.  The release profile of DuoCort's new form of treatment with once-a-day hydrocortisone dosing closely resembles the physiological secretion pattern. The data is published  in the European Journal of Endocrinology, a leading scientific journal for endocrinology.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155731.php">
<title>Microproteinuria: Indicator To Monitor CNI-Related Nephrotoxicity In Liver Transplant Recipients?</title>
<link>http://www.medicalnewstoday.com/articles/155731.php</link>
<description><![CDATA[Deterioration of renal function with CNI therapy has been widely reported in liver transplant recipients. Microproteinuria has been used to monitor the early changes of nephropathy in renal disease or cardiovascular events. However, whether microproteinuria could be used as an early and sensitive indicator to monitor CNI-related nephrotoxicity in liver transplant recipients has not been unequivocally addressed.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155739.php">
<title>DeCODE Discovers A Gene Linked To Risk Of Kidney Stones And Osteoporosis</title>
<link>http://www.medicalnewstoday.com/articles/155739.php</link>
<description><![CDATA[A discovery by scientists at deCODE genetics (Nasdaq: DCGN) and academic colleagues from Iceland, the Netherlands and Denmark has pointed to a common biological mechanism contributing to both kidney stones and decreased bone mineral density (BMD). About 60% of the population carry two copies of a single-letter variation in the human genome (SNP) on chromosome 21, putting them at roughly 65% greater likelihood of developing kidney stones than those who carry no copies.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155742.php">
<title>Vantia Therapeutics&#x27; Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect In Phase IIa Trial In Nocturia</title>
<link>http://www.medicalnewstoday.com/articles/155742.php</link>
<description><![CDATA[Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155659.php">
<title>Flu Shot May Be Less Effective After Transplant</title>
<link>http://www.medicalnewstoday.com/articles/155659.php</link>
<description><![CDATA[Kidney transplant patients have a weaker response to influenza immunization than healthy individuals, especially in the first six months after receiving a transplant, according to a study published in the July issue of the American Journal of Kidney Diseases, the official journal of the National Kidney Foundation.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155599.php">
<title>Are Antiperspirants Linked To Current Prostate And Breast Cancer Rates?</title>
<link>http://www.medicalnewstoday.com/articles/155599.php</link>
<description><![CDATA[UroToday.com - Prostate and breast cancer appear to be homologous cancer in males and females respectively. Both cancers share hormone etiologies and are treated with hormonal manipulation. The incidence of these two hormone-dependent cancers has steadily risen throughout the twentieth century.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155582.php">
<title>Positive CHMP Opinion For JAVLOR(R) In Metastatic Treatment Of Bladder Cancer After Failure Of A Prior Platinum-Containing Regimen</title>
<link>http://www.medicalnewstoday.com/articles/155582.php</link>
<description><![CDATA[Laboratoires Pierre Fabre announce that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant marketing authorisation for JAVLOR(R) as monotherapy in metastatic treatment of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155446.php">
<title>Improving The Management Of Patients With Chronic Kidney Disease - Roche Enzymatic Creatinine Assay For Specific And Reliable Results</title>
<link>http://www.medicalnewstoday.com/articles/155446.php</link>
<description><![CDATA[The Roche Creatinine Plus enzymatic creatinine assay, for use with cobas® or MODULAR Analytics analysers, offers a specific and accurate alternative to the less specific JaffÃ© method, ensuring clinically more reliable results in the management of patients with chronic kidney disease (CKD)1.  Users at GSTS (Guys, St Thomas', Serco) Pathology, London and the University Hospital, Coventry, amongst others, have found that the assay provides a more accurate assessment of renal function.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155406.php">
<title>UPMC Surgeon Performs 2,000th Prostate Cancer Surgery In Pittsburgh</title>
<link>http://www.medicalnewstoday.com/articles/155406.php</link>
<description><![CDATA[Joel B. Nelson, M.D., chairman of the University of Pittsburgh Medical Center's (UPMC) Department of Urology, performed his 2,000th radical prostatectomy at UPMC Shadyside, a milestone achieved by only a handful of surgeons worldwide. Radical prostatectomy, or removal of the entire prostate gland, is the most common treatment for patients with localized prostate cancer.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155420.php">
<title>Kidney Damage From Medical Imaging Procedures Can Cause Long-Term Health Problems</title>
<link>http://www.medicalnewstoday.com/articles/155420.php</link>
<description><![CDATA[Kidney injury that can arise after undergoing certain medical imaging procedures increases a patient's risk of having a stroke or heart attack over the next year or two, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that seemingly minor and reversible kidney damage from these common clinical procedures is a serious health threat.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155348.php">
<title>Older Kidney Transplant Patients Should More Often Consider Live Donors</title>
<link>http://www.medicalnewstoday.com/articles/155348.php</link>
<description><![CDATA[Almost half of kidney transplant candidates older than 60 who are put on the waiting list for a deceased-donor organ will die before getting a transplant, according to new findings from the University of Florida, Cleveland Clinic and Case Western Reserve University.    Wait times to receive a deceased donor kidney transplant have increased over the years, but this study is the first to define and quantify what this wait time means for older patients.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155240.php">
<title>New Faster-Acting Prostate Cancer Drug Hailed As &#x22;Significant Advance&#x22; In Improving Quality Of Life For Patients, UK</title>
<link>http://www.medicalnewstoday.com/articles/155240.php</link>
<description><![CDATA[FIRMAGON® (degarelix) a new fast-acting hormone treatment for advanced prostate cancer is being offically launched in the UK yesterday at the British Association of Urological Surgeons Annual Meeting in Glasgow.     Prostate cancer is the most common cancer in men, and over 35,000 cases a year (1) are diagnosed in the UK , with 10,239 men dying in 2007.(2)     Prostate cancer is fuelled by the male hormone testosterone.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155251.php">
<title>First Coast Medicare To Provide Case By Case Reimbursement For The Renessa(R) Treatment For Incontinence In Women</title>
<link>http://www.medicalnewstoday.com/articles/155251.php</link>
<description><![CDATA[Novasys Medical, Inc., a developer of innovative therapies in women's health, announced that as of July 1, 2009, First Coast Service Options, Inc. ("First Coast"), a large regional Medicare carrier serving over 3 million beneficiaries in Florida, Puerto Rico and the U.S.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/155008.php">
<title>A Urine Test For Appendicitis?</title>
<link>http://www.medicalnewstoday.com/articles/155008.php</link>
<description><![CDATA[ Appendicitis is the most common childhood surgical emergency, but the diagnosis can be challenging, especially in children, often leading to either unnecessary surgery in children without appendicitis, or a ruptured appendix and serious complications when the condition is missed. Now, emergency medicine physicians and scientists at the Proteomics Center at Children's Hospital Boston demonstrate that a protein detectable in urine might serve as a "biomarker" for appendicitis.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/154875.php">
<title>London Surgeon Pioneering Scarless Abdominal Surgery Using Belly Button</title>
<link>http://www.medicalnewstoday.com/articles/154875.php</link>
<description><![CDATA[  A London surgeon is pioneering a new way to remove abdominal organs through the belly button using an approach called single incision     laparoscopic surgery (SILS) which requires only a 10 mm cut in the navel to allow entry of a camera and all the surgical instruments and through     which organs like the appendix and gall bladder can be removed.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/154824.php">
<title>Fresenius Endorses PEAK Campaign Efforts To Reduce Dialysis Patient Mortality</title>
<link>http://www.medicalnewstoday.com/articles/154824.php</link>
<description><![CDATA[Fresenius Medical Care, which operates the nation's leading network of dialysis clinics, today endorsed the Performance Excellence and Accountability in Kidney Care (PEAK) campaign recently launched by Kidney Care Partners (KCP) - a coalition of patient advocates, dialysis professionals, care providers and manufacturers working together to improve quality of care for individuals with chronic kidney disease (CKD).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/154747.php">
<title>Role Of Overweight Status On Stone-Forming Risk Factors In Children: A Prospective Study</title>
<link>http://www.medicalnewstoday.com/articles/154747.php</link>
<description><![CDATA[UroToday.com - Gluttony is becoming an ever-increasing problem in our pediatric patients, and this is directly correlated to an increase risk of stone disease.     In this prospective study, 44 children who were being followed for obesity in the pediatric department were evaluated with respect to stone disease and stone forming risk factors using a 24-hour urine evaluation.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/154748.php">
<title>Survival In Prostate Cancer Patients &#x3E;/=70 Years After Radical Prostatectomy And Comparison To Younger Patients</title>
<link>http://www.medicalnewstoday.com/articles/154748.php</link>
<description><![CDATA[UroToday.com - In the online issue of the World Journal of Urology, a group headed by Professor Markus Hohenfellner compared the outcomes of radical prostatectomy (RP) in men younger and older than age 70 years.  They suggest that in well-selected men over age 70 years, the outcomes are comparable.     The study cohort consisted of 626 men who underwent RP at their institution between 1990 and 2006.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/9/6">
<title>Expression of multidrug resistance markers ABCB1 (MDR-1/ Pgp) and ABCC1 (MRP-1) in renal cell carcinoma.</title>
<link>http://www.biomedcentral.com/1471-2490/9/6</link>
<description><![CDATA[Background:
Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease.
Methods:
In this retrospective study the expression of two of these transporter efflux pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in archival material from 95 renal cell carcinoma patients.
Results:
In the first study investigating MDR-1 P-gp and MRP-1 protein expression patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of tumours studied showing MDR-1 P-gp and MRP-1 positivity.
Conclusion:
Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/9/5">
<title>Micropapillary bladder cancer: a review of Leon Berard Cancer Center experience</title>
<link>http://www.biomedcentral.com/1471-2490/9/5</link>
<description><![CDATA[Purpose: Micropapillary bladder cancer is a rare and aggressive variant of urothelial carcinoma. A retrospective review of our experience in management of patients with muscle-invasive or metastatic micropapillary bladder cancer was performed to better define the behavior of this disease.
Methods:
We reviewed the records of the 11 patients with micropapillary bladder cancer who were evaluated and treated at Leon Berard Cancer Center between 1994 and 2007, accounting for 1,2% of all urothelial tumors treated in this institution.
Results:
Mean patients age was 60 years. The majority of patients (72%) were diagnosed after 2004. After a median follow-up of 31.7 months, median overall survival was 19 months.Two patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed and had a disease free survival of 9.6 months.
Conclusion:
Micropapillary bladder cancer is probably an underreported variant of urothelial carcinoma associated with poor prognosis. Adjuvant chemotherapy might have a questionable efficacy and the optimal treatment strategy is yet to be defined.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/9/4">
<title>Outcome of recurrent and metastatic small cell carcinoma of the bladder </title>
<link>http://www.biomedcentral.com/1471-2490/9/4</link>
<description><![CDATA[Background:
Bladder small cell carcinoma is an uncommon tumour. Through a retrospective study we will present the evolution of recurrent and metastatic disease and outcome of patients treated at Léon-Bérard Cancer Centre.
Methods:
Only 15 patients having recurrent or metastatic bladder small cell carcinoma were treated at Léon-Bérard Cancer Centre between 1996 and 2007. The patients were divided in two groups: a mixed small cell carcinoma group (9 patients) and a pure small cell carcinoma group (6 patients). All the records and informations related to treatment and outcome of the 15 patients were retrospectively analyzed. Various characteristics of small cell carcinoma were investigated.
Results:
The median age of the 15 patients having recurrent or metastatic bladder small cell carcinoma and treated at Léon-Bérard Cancer Centre was 63 years and the disease was at stage IV for all cases. Nine patients were treated by chemotherapy. Four patients were treated by local radiotherapy (3 with radiotherapy without previous surgery and 1 with surgery followed by radiotherapy) and chemotherapy. One patient was treated by whole brain radiotherapy. And one patient died before treatment. After 52.4 months median follow up, 12 patients died. Median overall survival was 7.6 months. Survival probability at 1 year was 33%. Median overall survival was 9.9 months in the mixed small cell carcinoma group, and was only 4.6 months in the pure small cell carcinoma group. Survival probability at 1 year in the mixed small cell carcinoma group was 44% as compared to 17% in the pure small cell carcinoma group (Log-rank test: p = 0.228).
Conclusion:
Recurrent and metastatic bladder small cell carcinoma is associated with very poor prognosis. The pure bladder small cell carcinoma appears to have poorer outcome than the mixed bladder small cell carcinoma. Chemotherapy using platinum drugs is a mainstay treatment.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/9/3">
<title>Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience</title>
<link>http://www.biomedcentral.com/1471-2490/9/3</link>
<description><![CDATA[Background:
High-grade prostatic intraepithelial neoplasia (HGPIN) is a precursor lesion to prostate cancer (CaP). UK-based studies examining the occurrence of isolated HGPIN and subsequent risk of CaP are lacking. Our aim was to assess the occurrence of HGPIN in a regional UK population and to determine whether in a retrievable cohort of such patients that had repeat extended core biopsies, there was an elevated risk of CaP.
Methods:
A retrospective analysis of the pathology database was conducted at our institution (Lancashire Teaching Hospitals NHS Foundation Trust) for prostate biopsies recorded between January 2001 and December 2005 (all extended core biopsies). Those patients with isolated HGPIN on 1st set of biopsies were identified and, their clinical characteristics and pathological findings from subsequent biopsies (if any) were determined. The risk of CaP on subsequent biopsies based on presenting baseline PSA was stratified.
Results:
Of 2,192 biopsied patients, there were 88 cases of isolated HGPIN of which 67 patients underwent one or more repeat biopsies. In this repeat-biopsy group, 28 CaP diagnoses were made. Age at first biopsy (P  20 ng/ml – 87.5%.
Conclusion:
Based on our results, we recommend delaying the 1st repeat biopsy at low PSA range but to have a shorter interval to repeat biopsies at intermediate and higher PSA ranges.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/9/2">
<title>Focal therapy for prostate cancer: revolution or evolution?

</title>
<link>http://www.biomedcentral.com/1471-2490/9/2</link>
<description><![CDATA[The face of prostate cancer has been dramatically changed since the late 1980s when PSA was introduced as a clinical screening tool. More men are diagnosed with small foci of cancers instead of the advanced disease evident prior to PSA screening. Treatment options for these smaller tumors consist of expectant management, radiation therapy (brachytherapy and external beam radiotherapy) and surgery (cryosurgical ablation and radical prostatectomy). In the highly select patient, cancer specific survival employing any of these treatment options is excellent, however morbidity from these interventions are significant. Thus, the idea of treating only the cancer within the prostate and sparing the non-cancerous tissue in the prostate is quite appealing, yet controversial. Moving forward if we are to embrace the focal treatment of prostate cancer we must: be able to accurately identify index lesions within the prostate, image cancers within the prostate and methodically study the litany of focal therapeutic options available.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/9/1">
<title>Does the Biomarker Search Paradigm Need Re-Booting?</title>
<link>http://www.biomedcentral.com/1471-2490/9/1</link>
<description><![CDATA[The clinical problem of bladder cancer is its high recurrence and progression, and that the most sensitive and specific means of monitoring is cystoscopy, which is invasive and has poor patient compliance. Biomarkers for recurrence and progression could make a great contribution, but in spite of decades of research, no biomarkers are commercially available with the requisite sensitivity and specificity. In the post-genomic age, the means to search the entire genome for biomarkers has become available, but the conventional approaches to biomarker discovery are entirely inadequate to yield results with the new technology. Finding clinically useful biomarker panels with sensitivity and specificity equal to that of cystoscopy is a problem of systems biology.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/8/21">
<title>Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer</title>
<link>http://www.biomedcentral.com/1471-2490/8/21</link>
<description><![CDATA[Background:
The importance of immuno-histological detection of neuroendocrine differentiation in prostatic adenocarcinoma with respect to disease at presentation and Gleason grade is gaining acceptance. There is limited literature on the relative significance of three commonly used markers of NE differentiation i.e. Chromogranin A (CgA), Neuron specific enolase (NSE) and Synaptophysin (Syn). In the current work we have assessed the correlation of immuno-histological detection of neuroendocrine differentiation in prostatic adenocarcinoma with respect to disease at presentation and Gleason grade and to determine the relative value of various markers.Materials and methodsConsecutive samples of malignant prostatic specimens (Transurethral resection of prostate or radical retropubic prostatectomy) from 84 patients between January 1991 and December 1998 were evaluated by immunohistochemical staining (PAP technique) using selected neuroendocrine tumor markers i.e. Chromogranin A (CgA), Neuron specific enolase (NSE), and Synaptophysin (Syn). According to the stage at diagnosis, patients were divided into three groups. Group (i) included patients who had organ confined disease, group (ii) included patients with locally invasive disease, and group (iii) with distant metastasis. NE expression was correlated with Gleason sum and clinical stage at presentation and analyzed using Chi-Square test and one way ANNOVA.
Results:
The mean age of the patients was 70 ± 9.2 years. Group I had 14 patients, group II had 31 patients and group III had 39 patients. CgA was detected in 33 cases, Syn in 8 cases, and NSE in 44 cases. Expression of CgA was seen in 7% of group I, 37% in group II and 35% of group III patients (p 0.059). CgA (p 0.024) and NSE (p 0.006) had a significantly higher expression with worsening Gleason grade.
Conclusion:
CgA has a better correlation with disease at presentation than other markers used. Both NSE and CgA had increasing expression with worsening histological grade this correlation has a potential for use as a prognostic indicator. Limitations in the current work included small number and retrospective nature of work. The findings of this work needs validation in a larger cohort.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/8/20">
<title>Prostate Cancer - To screen, or not to screen, is that the question?</title>
<link>http://www.biomedcentral.com/1471-2490/8/20</link>
<description><![CDATA[There continues to be controversy regarding serum Prostate-Specific Antigen (PSA) and prostate cancer screening. We anxiously await the results of two large prospective randomized clinical trials (Prostate, Lung, Colon, and Ovary-PCLO screening trial in the US and European Randomized Study of Screening for Prostate Cancer-ERSPC in Europe) assessing the benefits of prostate cancer screening. However the true question to answer may be which cancer to treat and when should we treat it.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/8/19">
<title>The prognostic relevance of interactions between venous invasion, lymph node involvement and distant metastases in renal cell carcinoma after radical nephrectomy </title>
<link>http://www.biomedcentral.com/1471-2490/8/19</link>
<description><![CDATA[Background:
To investigate a possible prognostic significance of interactions between lymph node invasion (LNI), synchronous distant metastases (SDM), and venous invasion (VI) adjusted for mode of detection, Eastern Cooperative Oncology Group performance status (ECOG PS), erythrocyte sedimentation rate (ESR) and tumour size (TS) in 196 patients with renal cell carcinoma treated with radical nephrectomy.
Methods:
Median follow-up was 5.5 years (mean 6.9 years; range 0.01–19.4). The mode of detection, ECOG PS, ESR and TS were obtained from the patients' records. Vena cava invasion and distant metastases were detected by preoperative imaging. The surgical specimens were examined for pathological stage, LNI and VI.
Results:
The univariate analyses showed significant impact of VI, LNI, SDM, ESR and TS (p < 0.001), as well as mode of detection (p = 0.003) and ECOG PS (p = 0.002) on cancer specific survival. In multivariate analyses LNI was significantly associated with survival only in patients without SDM or VI (p < 0.001) with a hazard ratio of 9.0. LNI lost its prognostic significance when SDM or VI was present.
Conclusion:
Our findings underline the prognostic importance of the status of the lymph nodes. LNI, SDM, ESR, and VI were independently associated with cancer specific survival after radical nephrectomy. LNI provided the strongest prognostic information for patients without SDM or VI whereas SDM and VI had strongest impact on survival when there was no nodal involvement.]]></description>
</item>

<item rdf:about="http://www.biomedcentral.com/1471-2490/8/18">
<title>Transurethral resection of the prostate In Northern Nigeria, problems and prospects</title>
<link>http://www.biomedcentral.com/1471-2490/8/18</link>
<description><![CDATA[Background:
Benign prostatic hyperplasia (BPH) is the commonest disease of the urinary tract afflicting the ageing male and is the commonest neoplastic disease in men aged 50 years and above.Transurethral prostatectomy (TURP) is the ultimate treatment of choice for benign prostatic hyperplasia (BPH) due mainly to the preference of minimally invasive surgery, long term relief of symptoms and cost effectiveness. It is however not available to the majority of Nigerians in need of prostatic surgery in Public Health Institutions.
Methods:
The records of patients who underwent prostatectomy in Aminu Kano Teaching Hospital, over the period June 2001 to July 2007 were examined. The bio data of patients and laboratory investigations performed were retrieved.
Results:
Five Hundred and forty two patients were operated upon, out of which 40 were excluded due to open prostatectomy (22 patients), bladder neck stenosis (16 patients) or bladder tumour around the trigon (2 patients). The age range of the patients was 47–110 years with a mean of 67.2 years. 289 patients (80.1%) had urethral catheter in situ at presentation and 11 (3%) patients had suprapubic cystostomy of which only 3 (0.85%) had combined urethral stricture and BPH.Only 131 (26%) had their PSA measured which ranged from 2–100 ng/ml out of which 39(29.8% n = 131) patients had more than 4 ng/ml and cancer of the prostate and 1(0.8%, n = 131) patient had a PSA level of 4 ng/ml and malignant prostate.Hospital stay was 1–32 days (mean 7.9) and the mean follow up period was 5.6 months (range 0–60) and there were 17.5% complications comprising of urinary tract infection (UTI) 7.2%, Orchitis 2.2%, urinary incontinence 0.6%, atonic bladder 1%, erectile dysfunction 0.6%, cerebrovascular accident 0.4%, myocardial infarction 0.4%, deep vein thrombosis 0.4% and disseminated intravascular coagulopathy (DIC) 0.6% and 1.2% mortality. The cost of treatment inclusive of pre-admission investigations was US$ 615.00 (range US$ 300–1,300)
Conclusion:
Despite advances in minimally invasive therapy for LUTH/BPH, TURP is the optimum treatment of choice for the ageing male of sub-Saharan Africa. It is however not available to the majority of patients in this region due to poor health allocation and inadequate facilities and training.]]></description>
</item>

</rdf:RDF>